Xbrane Biopharma AB (publ) (XBRANE.ST)
SEK 0.16
(-3.53%)
SEK 0.16
(-3.53%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -310.42 Million SEK | -86.76% |
| 2022 | -166.21 Million SEK | 7.86% |
| 2021 | -180.39 Million SEK | 19.56% |
| 2020 | -224.25 Million SEK | -36.22% |
| 2019 | -164.62 Million SEK | -1342.14% |
| 2018 | -11.41 Million SEK | 74.47% |
| 2017 | -44.71 Million SEK | -34.6% |
| 2016 | -33.22 Million SEK | -187.61% |
| 2015 | -11.55 Million SEK | -348.73% |
| 2014 | -2.57 Million SEK | -22.15% |
| 2013 | -2.1 Million SEK | -153.07% |
| 2012 | -832.72 Thousand SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -89.27 Million SEK | -7.24% |
| 2024 Q2 | -63.66 Million SEK | 28.69% |
| 2024 Q3 | -37.42 Million SEK | 41.22% |
| 2023 Q3 | -89.71 Million SEK | -1.21% |
| 2023 Q4 | -83.24 Million SEK | 7.21% |
| 2023 Q2 | -88.64 Million SEK | -54.78% |
| 2023 FY | -310.42 Million SEK | -86.76% |
| 2023 Q1 | -57.27 Million SEK | -4.06% |
| 2022 Q2 | -32.4 Million SEK | 11.91% |
| 2022 Q4 | -55.04 Million SEK | -31.07% |
| 2022 FY | -166.21 Million SEK | 7.86% |
| 2022 Q1 | -36.78 Million SEK | -14.44% |
| 2022 Q3 | -41.99 Million SEK | -29.6% |
| 2021 Q2 | -58.41 Million SEK | -13.62% |
| 2021 Q1 | -51.41 Million SEK | 18.29% |
| 2021 FY | -180.39 Million SEK | 19.56% |
| 2021 Q4 | -32.14 Million SEK | 24.73% |
| 2021 Q3 | -42.7 Million SEK | 26.89% |
| 2020 Q2 | -53.19 Million SEK | -9.28% |
| 2020 FY | -224.25 Million SEK | -36.22% |
| 2020 Q4 | -62.91 Million SEK | -9.4% |
| 2020 Q3 | -57.51 Million SEK | -8.12% |
| 2020 Q1 | -48.68 Million SEK | 12.4% |
| 2019 Q2 | -43.98 Million SEK | -33.57% |
| 2019 Q3 | -32.12 Million SEK | 26.96% |
| 2019 Q4 | -55.57 Million SEK | -72.98% |
| 2019 FY | -164.62 Million SEK | -1342.14% |
| 2019 Q1 | -32.93 Million SEK | -2.41% |
| 2018 Q3 | 60.85 Million SEK | 291.87% |
| 2018 Q2 | -31.71 Million SEK | -277.73% |
| 2018 Q4 | -32.15 Million SEK | -152.84% |
| 2018 Q1 | -8.39 Million SEK | 56.5% |
| 2018 FY | -11.41 Million SEK | 74.47% |
| 2017 Q4 | -19.3 Million SEK | -118.37% |
| 2017 Q3 | -8.83 Million SEK | 5.01% |
| 2017 Q2 | -9.3 Million SEK | 7.9% |
| 2017 FY | -44.71 Million SEK | -34.6% |
| 2017 Q1 | -10.1 Million SEK | 0.71% |
| 2016 Q2 | -7.52 Million SEK | -38.55% |
| 2016 Q3 | -10.02 Million SEK | -33.25% |
| 2016 Q1 | -5.42 Million SEK | -7.84% |
| 2016 Q4 | -10.17 Million SEK | -1.52% |
| 2016 FY | -33.22 Million SEK | -187.61% |
| 2015 Q2 | -1.32 Million SEK | -22.68% |
| 2015 Q1 | -1.08 Million SEK | 18.13% |
| 2015 FY | -11.55 Million SEK | -348.73% |
| 2015 Q4 | -5.03 Million SEK | -22.79% |
| 2015 Q3 | -4.1 Million SEK | -208.96% |
| 2014 Q3 | -614.54 Thousand SEK | 0.0% |
| 2014 Q4 | -1.32 Million SEK | -115.01% |
| 2014 FY | -2.57 Million SEK | -22.15% |
| 2013 FY | -2.1 Million SEK | -153.07% |
| 2012 FY | -832.72 Thousand SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | -24.678% |
| Ziccum AB (publ) | -21.56 Million SEK | -1339.824% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -1792.726% |
| BioArctic AB (publ) | 252.64 Million SEK | 222.873% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -36636.805% |
| Mendus AB (publ) | -100.65 Million SEK | -208.421% |
| Genovis AB (publ.) | 54.22 Million SEK | 672.488% |
| Intervacc AB (publ) | -93.57 Million SEK | -231.726% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -1901.199% |
| Active Biotech AB (publ) | -46.48 Million SEK | -567.813% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 1823.727% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | -460.164% |
| Aptahem AB (publ) | -10.1 Million SEK | -2972.077% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 3.446% |
| Kancera AB (publ) | -65.04 Million SEK | -377.27% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | -130.599% |
| Fluicell AB (publ) | -26.87 Million SEK | -1054.902% |
| Saniona AB (publ) | -81.06 Million SEK | -282.935% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -2409.304% |
| Biovica International AB (publ) | -126.07 Million SEK | -146.227% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | -630.328% |
| AcouSort AB (publ) | -17.48 Million SEK | -1675.182% |
| Xintela AB (publ) | -57.23 Million SEK | -442.342% |
| Abliva AB (publ) | -96.54 Million SEK | -221.525% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 4.425% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -8756.662% |
| OncoZenge AB (publ) | -15.9 Million SEK | -1852.119% |
| Amniotics AB (publ) | -29.07 Million SEK | -967.747% |
| 2cureX AB (publ) | -36.36 Million SEK | -753.686% |
| CombiGene AB (publ) | -36.3 Million SEK | -755.047% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -2020.396% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 19.243% |
| Camurus AB (publ) | 532.35 Million SEK | 158.312% |
| Corline Biomedical AB | -1.78 Million SEK | -17261.633% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | -71.729% |
| Isofol Medical AB (publ) | -41.68 Million SEK | -644.73% |
| I-Tech AB | 24.43 Million SEK | 1370.415% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 60.631% |
| Cyxone AB (publ) | -21.66 Million SEK | -1333.11% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | -192.951% |
| Biosergen AB | -27.26 Million SEK | -1038.551% |
| Cantargia AB (publ) | -290.01 Million SEK | -7.037% |
| NextCell Pharma AB | -43.17 Million SEK | -619.043% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | -71.729% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -1715.752% |
| Nanologica AB (publ) | -69.96 Million SEK | -343.7% |
| SynAct Pharma AB | -224.49 Million SEK | -38.277% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | -602.703% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -1195.911% |
| LIDDS AB (publ) | -40.67 Million SEK | -663.205% |
| Lipum AB (publ) | -37.25 Million SEK | -733.269% |
| BioInvent International AB (publ) | -369.94 Million SEK | 16.088% |
| Alzinova AB (publ) | -16.52 Million SEK | -1778.865% |
| Oncopeptides AB (publ) | -253.44 Million SEK | -22.482% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -4755.528% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | -169.764% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -1441.417% |
| Simris Alg AB (publ) | -36.63 Million SEK | -747.348% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | -111.798% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | -179.88% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -2583.953% |